loading
Neurosense Therapeutics Ltd stock is traded at $1.24, with a volume of 57,904. It is up +0.81% in the last 24 hours and down -1.59% over the past month. NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.23
Open:
$1.25
24h Volume:
57,904
Relative Volume:
0.24
Market Cap:
$24.36M
Revenue:
-
Net Income/Loss:
$-13.76M
P/E Ratio:
-0.9612
EPS:
-1.29
Net Cash Flow:
-
1W Performance:
-7.46%
1M Performance:
-1.59%
6M Performance:
-6.77%
1Y Performance:
+150.51%
1-Day Range:
Value
$1.21
$1.25
1-Week Range:
Value
$1.12
$1.38
52-Week Range:
Value
$0.4313
$2.33

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name
Name
Neurosense Therapeutics Ltd
Name
Phone
-
Name
Address
-
Name
Employee
16
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
NRSN's Discussions on Twitter

Neurosense Therapeutics Ltd Stock (NRSN) Latest News

pulisher
Oct 31, 2024

Neurosense Therapeutics Secures $30 Million Equity Deal - TipRanks

Oct 31, 2024
pulisher
Oct 31, 2024

NeuroSense Therapeutics Announces Private Placement with Senior - GuruFocus.com

Oct 31, 2024
pulisher
Oct 30, 2024

NeuroSense Completes Key ALS Trial Phase - TipRanks

Oct 30, 2024
pulisher
Oct 30, 2024

NeuroSense Therapeutics : INFORMATION CONTAINED IN THIS REPORT ON FORM 6 K Form 6 K - Marketscreener.com

Oct 30, 2024
pulisher
Oct 28, 2024

NeuroSense schedules FDA meeting for ALS drug trial - Investing.com

Oct 28, 2024
pulisher
Oct 28, 2024

NeuroSense Therapeutics Advances ALS Drug Development Plans - TipRanks

Oct 28, 2024
pulisher
Oct 28, 2024

NeuroSense schedules FDA meeting for ALS drug trial By Investing.com - Investing.com Australia

Oct 28, 2024
pulisher
Oct 28, 2024

NeuroSense Therapeutics Ltd. Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - Marketscreener.com

Oct 28, 2024
pulisher
Oct 28, 2024

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission - StockTitan

Oct 28, 2024
pulisher
Oct 28, 2024

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission - Benzinga

Oct 28, 2024
pulisher
Oct 24, 2024

NRSNNeuroSense Therapeutics Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Oct 24, 2024
pulisher
Oct 24, 2024

NeuroSense’s PrimeC Shows Potential in ALS Treatment - TipRanks

Oct 24, 2024
pulisher
Oct 24, 2024

NeuroSense Therapeutics : New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients Form 6 K - Marketscreener.com

Oct 24, 2024
pulisher
Oct 24, 2024

Neurosense Therapeutics Ltd. Announces Transformative Findings from Its Paradigm Clinical Trial of PrimeC - Marketscreener.com

Oct 24, 2024
pulisher
Oct 17, 2024

NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market - Nasdaq

Oct 17, 2024
pulisher
Oct 17, 2024

NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market | StreetInsider.com - Financial Content

Oct 17, 2024
pulisher
Oct 16, 2024

NeuroSense seeks early Canada approval for ALS drug By Investing.com - Investing.com Nigeria

Oct 16, 2024
pulisher
Oct 15, 2024

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates - Citizentribune

Oct 15, 2024
pulisher
Oct 15, 2024

NeuroSense seeks early Canada approval for ALS drug - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

NeuroSense Targets Key ALS Drug Market in Canada - TipRanks

Oct 15, 2024
pulisher
Oct 09, 2024

NeuroSense Targets Early ALS Drug Approval in Canada - TipRanks

Oct 09, 2024
pulisher
Oct 09, 2024

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada - PR Newswire

Oct 09, 2024
pulisher
Oct 07, 2024

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting - PR Newswire

Oct 07, 2024
pulisher
Oct 05, 2024

NeuroSense Therapeutics Ltd. Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study - Marketscreener.com

Oct 05, 2024
pulisher
Oct 03, 2024

XTX Topco Ltd Invests $37,000 in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World

Oct 03, 2024
pulisher
Sep 30, 2024

NeuroSense Therapeutics Reports Mid-Year Financials - TipRanks

Sep 30, 2024
pulisher
Sep 25, 2024

In the Green: NeuroSense Therapeutics Ltd (NRSN) Closes at 1.25, Up/Down -3.50 from Previous Day - The Dwinnex

Sep 25, 2024
pulisher
Sep 25, 2024

NeuroSense extends PrimeC patent protection to 2042 By Investing.com - Investing.com Australia

Sep 25, 2024
pulisher
Sep 25, 2024

NeuroSense back in line with Nasdaq bid price rule By Investing.com - Investing.com Australia

Sep 25, 2024
pulisher
Sep 24, 2024

NeuroSense back in line with Nasdaq bid price rule - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

NeuroSense extends PrimeC patent protection to 2042 - Investing.com

Sep 24, 2024
pulisher
Sep 24, 2024

NeuroSense Back on Track with NASDAQ Compliance - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's - PR Newswire

Sep 24, 2024
pulisher
Sep 24, 2024

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - PR Newswire

Sep 24, 2024
pulisher
Sep 20, 2024

Naspers (OTCMKTS:NPSNY) Share Price Passes Above 50-Day Moving Average of $39.49 - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

SenesTech stock hits 52-week low at $2.4 amid sharp decline - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

This £300 health scan has a 10k waitlist — I tried it and found out why it's so worth it - Evening Standard

Sep 19, 2024
pulisher
Sep 19, 2024

Sachin Tendulkar stock jumps 8% after it gets buy call for an upside of 20% - Trade Brains

Sep 19, 2024
pulisher
Sep 17, 2024

Neuralink Blindsight receives FDA Breakthrough Device Designation for visually impaired patients - Shacknews

Sep 17, 2024
pulisher
Sep 17, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Sep 17, 2024
pulisher
Sep 17, 2024

Quest Partners LLC Sells 3,065 Shares of Napco Security Technologies, Inc. (NASDAQ:NSSC) - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Surgery-free Neuralink rival enables thought-controlled smart home - New Atlas

Sep 17, 2024
pulisher
Sep 17, 2024

Mind Medicine (MindMed) (NASDAQ:MNMD) Given New $14.00 Price Target at Canaccord Genuity Group - Defense World

Sep 17, 2024
pulisher
Sep 16, 2024

NeuroSense Embarks on HIPAA Compliance Journey - TipRanks

Sep 16, 2024
pulisher
Sep 15, 2024

Quest Partners LLC Has $298,000 Position in Northern Trust Co. (NASDAQ:NTRS) - Defense World

Sep 15, 2024
pulisher
Sep 10, 2024

NeuroSense Therapeutics Ltd: -52.36% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle

Sep 10, 2024
pulisher
Sep 09, 2024

NeuroSense Reports Positive Drug Study Results - TipRanks

Sep 09, 2024
pulisher
Sep 07, 2024

NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.9% - Defense World

Sep 07, 2024
pulisher
Sep 04, 2024

It would be worthwhile to take a closer look at NeuroSense Therapeutics Ltd (NRSN) - US Post News

Sep 04, 2024
pulisher
Sep 04, 2024

Lonza, NeuroSense Enter Alliance For ALS Candidate - Contract Pharma

Sep 04, 2024
pulisher
Aug 30, 2024

NeuroSense Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks

Aug 30, 2024

Neurosense Therapeutics Ltd Stock (NRSN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):